Literature DB >> 11741472

Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.

P D Greenspan1, K L Clark, R A Tommasi, S D Cowen, L W McQuire, D L Farley, J H van Duzer, R L Goldberg, H Zhou, Z Du, J J Fitt, D E Coppa, Z Fang, W Macchia, L Zhu, M P Capparelli, R Goldstein, A M Wigg, J R Doughty, R S Bohacek, A K Knap.   

Abstract

Cathepsin B is a member of the papain superfamily of cysteine proteases and has been implicated in the pathology of numerous diseases, including arthritis and cancer. As part of an effort to identify potent, reversible inhibitors of this protease, we examined a series of dipeptidyl nitriles, starting with the previously reported Cbz-Phe-NH-CH(2)CN (19, IC(50) = 62 microM). High-resolution X-ray crystallographic data and molecular modeling were used to optimize the P(1), P(2), and P(3) substituents of this template. Cathepsin B is unique in its class in that it contains a carboxylate recognition site in the S(2)' pocket of the active site. Inhibitor potency and selectivity were enhanced by tethering a carboxylate functionality from the carbon alpha to the nitrile to interact with this region of the enzyme. This resulted in the identification of compound 10, a 7 nM inhibitor of cathepsin B, with excellent selectivity over other cysteine cathepsins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741472     DOI: 10.1021/jm010206q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

1.  A geometry force field which converts low-resolution X-ray models to structures with properties found at ultra high resolution.

Authors:  Colin McMartin
Journal:  Protein Sci       Date:  2011-12-05       Impact factor: 6.725

2.  Structural basis for inhibition of cathepsin B drug target from the human blood fluke, Schistosoma mansoni.

Authors:  Adéla Jílková; Pavlína Rezácová; Martin Lepsík; Martin Horn; Jana Váchová; Jindrich Fanfrlík; Jirí Brynda; James H McKerrow; Conor R Caffrey; Michael Mares
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

3.  Targeting Cathepsin B for Cancer Therapies.

Authors:  Hang Ruan; Susan Hao; Peter Young; Hongtao Zhang
Journal:  Horiz Cancer Res       Date:  2015 2nd Quarter

4.  Oxygen additions in serial femtosecond crystallographic protein structures.

Authors:  Jimin Wang
Journal:  Protein Sci       Date:  2016-07-26       Impact factor: 6.725

5.  Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability.

Authors:  Jeffery D Zwicker; Nicolas A Diaz; Alfredo J Guerra; Paul D Kirchhoff; Bo Wen; Duxin Sun; Vern B Carruthers; Scott D Larsen
Journal:  Bioorg Med Chem Lett       Date:  2018-03-09       Impact factor: 2.823

6.  Photoactivated inhibition of cathepsin K in a 3D tumor model.

Authors:  Mackenzie K Herroon; Rajgopal Sharma; Erandi Rajagurubandara; Claudia Turro; Jeremy J Kodanko; Izabela Podgorski
Journal:  Biol Chem       Date:  2016-06-01       Impact factor: 3.915

7.  Ru(ii) polypyridyl complexes as photocages for bioactive compounds containing nitriles and aromatic heterocycles.

Authors:  Ao Li; Claudia Turro; Jeremy J Kodanko
Journal:  Chem Commun (Camb)       Date:  2018-02-01       Impact factor: 6.222

8.  Cathepsin B Inhibitors: Combining Dipeptide Nitriles with an Occluding Loop Recognition Element by Click Chemistry.

Authors:  Janina Schmitz; Tianwei Li; Ulrike Bartz; Michael Gütschow
Journal:  ACS Med Chem Lett       Date:  2015-12-28       Impact factor: 4.345

9.  Multi-conformation 3D QSAR study of benzenesulfonyl-pyrazol-ester compounds and their analogs as cathepsin B inhibitors.

Authors:  Zhigang Zhou; Yanli Wang; Stephen H Bryant
Journal:  J Mol Graph Model       Date:  2011-07-07       Impact factor: 2.518

10.  Cloning and expression of the major secreted cathepsin B-like protein from juvenile Fasciola hepatica and analysis of immunogenicity following liver fluke infection.

Authors:  Ruby H P Law; Peter M Smooker; James A Irving; David Piedrafita; Rebecca Ponting; Nicholas J Kennedy; James C Whisstock; Robert N Pike; Terry W Spithill
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.